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Resistance to hepatitis C virus (HCV) inhibitors targeting viral enzymes has been observed in in vitro
replicon studies and during clinical trials. The factors determining the emergence of resistance and the
changes in the viral quasispecies population under selective pressure are not fully understood. To assess the
dynamics of variants emerging in vitro under various selective pressures with TMC380765, a potent macrocyclic
HCV NS3/4A protease inhibitor, HCV genotype 1b replicon-containing cells were cultured in the presence of
a low, high, or stepwise-increasing TMC380765 concentration(s). HCV replicon RNA from representative
samples thus obtained was analyzed using (i) population, (ii) clonal, and (iii) 454 deep sequencing technolo-
gies. Depending on the concentration of TMC380765, distinct mutational patterns emerged. In particular,
culturing with low concentrations resulted in the selection of low-level resistance mutations (F43S and A156G),
whereas high concentrations resulted in the selection of high-level resistance mutations (A156V, D168V, and
D168A). Clonal and 454 deep sequencing analysis of the replicon RNA allowed the identiﬁcation of low-
frequency preexisting mutations possibly contributing to the mutational pattern that emerged. Stepwise-
increasing TMC380765 concentrations resulted in the emergence and disappearance of multiple replicon
variants in response to the changing selection pressure. Moreover, two different codons for the wild-type amino
acids were observed at certain NS3 positions within one population of replicons, which may contribute to the
emerging mutational patterns. Deep sequencing technologies enabled the study of minority variants present in
the HCV quasispecies population present at baseline and during antiviral drug pressure, giving new insights
into the dynamics of resistance acquisition by HCV.
Chronic hepatitis C virus (HCV) infection can lead to liver
ﬁbrosis, cirrhosis, hepatocellular carcinoma, and ultimately
liver failure. Approximately 170 million people worldwide are
infected with HCV (54a). The current standard of care consists
of pegylated alpha interferon (Peg-IFN) plus ribavirin (RBV),
providing limited efﬁcacy for genotype 1-infected patients, i.e.,
a sustained virological response (SVR) in 40 to 50% of the
patients. Moreover, Peg-IFN/RBV therapy is associated with
signiﬁcant adverse events (9). Therefore, direct antiviral agents
(DAA) (previously also known as “speciﬁcally targeted antivi-
ral therapies for hepatitis C” or STAT-C) have been a major
focus of drug discovery efforts over the last 2 decades. Several
NS3/4A (protease), NS5A, and NS5B (polymerase) inhibitors
either alone or in combination with Peg-IFN/RBV have re-
cently shown potent antiviral effects in HCV-infected patients
(22, 36). However, viral resistance to these novel agents can
occur rapidly when they are dosed as monotherapy (43, 49).
Because of the high mutation rate of the HCV polymerase
(10
3 to 10
5 misincorporations per nucleotide copied [11])
and the high viral production rates in vivo (approximately 10
12
viruses per patient per day [37]), it can be assumed that HCV
exists as a diverse population of nonidentical but closely re-
lated viral genomes, referred to as a quasispecies (10). A viral
quasispecies is characterized by a dominant nucleotide se-
quence, called a master sequence, and a surrounding mutant
spectrum, which can harbor minority subpopulations (42). Al-
though in theory all single and double mutants are produced
daily in an infected person (6, 40), it is important to note that
mutation rates are not equally distributed over the entire ge-
nome and that additional factors, such as viral ﬁtness and the
replication environment, determine whether a mutation be-
comes ﬁxed in a viral quasispecies population (12). The
diversity of the viral variants present in an infected individ-
ual facilitates the adaptation of the quasispecies to external
pressure, such as antiviral treatment, improving the survival
chances of the population (53). The speed of such adapta-
tion depends mainly on the turnover of the viral nucleic acid
acting as a source of new viral genomes. Whereas in HIV the
rapid turnover of infected CD4
 T lymphocytes is respon-
sible for the rapid turnover of nucleic acids, in HCV rapid
turnover is explained by the short half-life (10 h) of HCV
RNA strands in the hepatocyte (47). However, if mutation
rates exceed a certain limit, called the error threshold, del-
eterious mutations will accumulate and the viral population
will become extinct (4).
Recent reports have demonstrated that mutations known to
affect the activities of DAA compounds in vitro are present in
some treatment-naive patients as either dominant or minority
species (6, 13, 19, 21, 27). With the eradication of variants
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11124susceptible to the antiviral drugs, resistant viruses initially
present as minority species may expand to occupy the freed
replicative space, thus becoming the dominant master se-
quence (1); this may lead to failure of the antiviral regimen. In
HIV it has been shown that minority species can play an
important role in the accelerated evolution toward resistance
to antiretroviral drugs (5). The extent to which preexisting
HCV variants may compromise treatment with DAAs, how-
ever, is not yet fully understood (3). Depending on the con-
centration of the antiviral agent, different resistance proﬁles
seem to emerge. In clinical studies, a correlation was noted
between the plasma trough levels of the NS3/4A inhibitor
telaprevir, the virological response, and the mutations respon-
sible for the drug-resistant phenotype (43). In patients with a
low exposure to telaprevir, variants carrying mutations with
low resistance to telaprevir in vitro were observed, while higher
drug levels were associated with variants conferring a greater
degree of resistance in vitro. Correlations between the inhibitor
concentration and the mutation proﬁle were also described in
in vitro studies (44, 50, 51).
HCV replicon cell culture systems have been widely used to
characterize resistance against antiviral inhibitors and to assess
the impact of resistance mutations on drug susceptibility and
replication ﬁtness in vitro (8, 15). Although the information on
resistance mutations observed with DAA during clinical trials
is still limited, mutations identiﬁed in vitro appear to be pre-
dictive for those mutations that may emerge in patients (17,
20). In addition, analysis of the genetic variability and diversity
of a long-term HCV replicon-containing cell culture has shown
that mutations accumulate over time at rates comparable to
those observed in vivo: (3.5 to 4.8)  10
3 in vitro versus (1.4
to 1.9)  10
3 in vivo base substitutions/site/year (16). Hence,
HCV replicon systems are considered a useful and relevant
surrogate system for analyzing the evolutionary dynamics and
variations of HCV in response to selection pressure.
The detailed study of the dynamics of viral variants present
in a quasispecies population has long been hampered by the
lack of sensitive sequencing methods. The recent development
of deep sequencing technologies may facilitate a better under-
standing of the genetic composition and natural evolution of
viral quasispecies in the presence of antiviral drugs (30, 34, 54).
Indeed, studies of HIV suggest that these more-sensitive se-
quencing technologies detect additional minority variants for
both treatment-naive and treatment-experienced patients
which could impact the clinical outcome of antiretroviral ther-
apy and may provide important information for treatment
planning (2, 23, 41, 46).
TMC380765 (Fig. 1) is a macrocyclic inhibitor of the HCV
NS3/4A protease and a potent inhibitor of HCV RNA repli-
cation in vitro, with median 50% effective concentration (EC50)
and 90% effective concentration (EC90) values of 35 nM and
106 nM, respectively, in the Huh7-Luc replicon using a lucif-
erase readout (25, 39). Other examples of macrocyclic NS3/4A
inhibitors include BILN-2061, ITMN-191, MK7009, and
TMC435. To assess the effect of its selective pressure on the
composition of the replicon population, selection experiments
were performed with different concentrations of TMC380765
and sequence changes were determined with population,
clonal, and 454 deep sequencing technologies.
MATERIALS AND METHODS
TMC380765. TMC380765 was synthesized in-house as described previ-
ously (9).
Cell culture and selection with TMC380765. Huh7-Luc cells (kindly provided
by R. Bartenschlager [adapted from reference 26]), containing the genotype-1b
(con1b-based) bicistronic subgenomic replicon (clone ET) encoding a ﬁreﬂy
luciferase reporter with the cell culture adaptive mutations E1202G, T1280I, and
K1846T in the HCV genome, were grown in Dulbecco’s minimal essential me-
dium (DMEM) supplemented with 10% fetal calf serum, 1% L-glutamine, 0.04%
gentamicin, and 0.75 mg/ml G418. To select for resistance against TMC380765,
3  10
5 replicon-containing cells were seeded in a 10-cm
2 tissue culture dish and
cultured for 4 to 6 weeks in the presence of TMC380765 and G418. Replicon-
containing cells were split twice per week at a ratio of 1:2 to 1:5, and fresh
TMC380765-containing medium was added regardless of whether the cell cul-
ture was split. For “low-dose” experiments, 100 nM TMC380765 was used, and
“high-dose” experiments used a concentration of 1,000 nM. The concentration of
TMC380765 was increased in every passage in the “stepwise-increasing inhibi-
tor” experiments (here referred to as experiments A and B): 0 (pretreatment),
20, 40, 60, 80, 160, 240, 320, 400, 480, 560, 640, 720, 800, 880, and 1,000 nM. As
a negative control, replicon-containing Huh7-Luc cells were cultured in the
absence of compound. At every passage, approximately 10,000 to 15,000 cells
were taken from culture, diluted in 1 ml of cell culture medium, and frozen at
80°C for RNA extraction.
RNA extraction and PCR. Total RNA was extracted from 10,000 to 15,000
cells using an automated EasyMag extraction robot (NucliSens; bioMe ´rieux) and
eluted in 25 l of elution buffer. cDNA for high- and low-dose selection exper-
iments and for experiment A was generated by reverse transcription using an
NS3 gene-speciﬁc PRO5543R (CCCGATTGCCTTCTGTTTG) primer and the
Expand reverse transcriptase (RT) kit (Roche). Nested PCR for the NS3/4A
gene was performed using the Expand HF system (Roche) and the primer
combinations PRO5543R and Prot2519F (GGCTGAAGGATGCCCAGA
AGG) for outer and PRO5502R (CCTGTTCGATGTAAGGGAGG) and
Prot2662F (GATAATACCATGGCGCCTATTACGGCC) for inner PCR at an
annealing temperature of 58°C. cDNA for experiment B was generated using the
AccuScript high-ﬁdelity 1st-strand cDNA synthesis kit (Stratagene) as de-
scribed by the manufacturers using the random primers provided with the kit.
Two independent sets of primer pairs were designed: primer pair one, con-
taining 1b_1_fwd_SG, (CGTATTCAACAAGGGGCTGA; nucleotides 3541
to 3560 in the encephalomyocarditis virus [ECMV] internal ribosome entry
site [IRES] of the HCV replicon) and HCV1b_3739R (ACCAAGTAAAGG
TCCGAGCTG; nucleotides 4009 to 4026 in NS3), and primer pair 2 con-
taining HCV1b_3648F (AATGTAGACCAGGACCTCGTCG; nucleotides
3938 to 3959 in NS3) and HCV1b_4016R (CACCTGGAATGTCTGCGG
TAC; nucleotides 4286 to 4306 in NS3). These primer pairs were used to
generate two amplicons: amplicon 1b_1 (488 bp) and 1b_2 (369 bp), covering
the complete protease domain (amino acids 1 to 181) of NS3. NS3 protease
amino acid positions 1 to 99 are covered by the ﬁrst amplicon; amino acid
positions 85 to 192 are covered by the second amplicon.
For bidirectional pyrosequencing purposes, A and B sequence adaptors were
ligated to forward and reverse primers, respectively, and additional multiplex
identiﬁers (MIDs) (i.e., short barcode sequences) were attached to the adaptor-
ligated primers to allow pooling of samples. For PCR, Phusion Hot Start high-
ﬁdelity DNA polymerase (Finnzymes) was used to overcome possible primer
FIG. 1. Structural formulae of TMC380765.
VOL. 84, 2010 EVOLUTION OF MULTIPLE IN VITRO HCV REPLICON VARIANTS 11125dimer formation and ensure accuracy. To maximize the amount of input tem-
plates and to minimize variation due to PCR drift, seven replicate RT-PCRs
were carried out for each sample and subsequently pooled for sequence analysis
(48, 52).
For standard Sanger sequencing of experiment B, the ﬁrst 181 amino acids
(aa) of NS3 were ampliﬁed as one amplicon using the forward primer
1b_1_fwd_SG and reverse primer HCV1b_4016R, resulting in an amplicon of
765 bp.
Cloning and standard Sanger sequencing. NS3/4A amplicons derived from
cultures of high- and low-dose selection experiments and of experiment A and
NS3 amplicons from experiment B were puriﬁed (PCR puriﬁcation kit; Qiagen),
bacterially cloned, and sequenced (Agowa Berlin, Germany). For clonal analysis
of experiments A and B, 24 and 48 clones per sample were analyzed, respectively.
Sequence editing and contig assembly were performed using the SeqScape v2.5
software program (Applied Biosystems).
454 Deep sequencing (GS-FLX). 454 deep sequencing analysis of experiment
A was performed at the 454 sequencing center (Branford, CT). To this end, 2-kb
NS3/4A PCR amplicons were prepared and nebulized to generate smaller frag-
ments for GS-FLX shotgun DNA library preparation followed by sequencing.
Sequencing results were analyzed in-house using the EMBOSS software program
(http://emboss.sourceforge.net/) and custom Perl scripts.
Deep sequencing, library preparation, and analysis of overlapping amplicons
of samples of experiment B and of the replicon control experiment were per-
formed using the GS-FLX amplicon approach. Sequencing data were analyzed
using the AVA software program.
The average number of sequence reads per position ( coverage) was between
2,600 and 12,000 (experiment A) or between 800 and 15,000 (experiment B).
Coverage of the second amplicon of the samples from 800 and 880 nM concen-
trations in experiment B was very low (100 reads). No replicon RNA copy
numbers were determined in experiment A. The average number of HCV rep-
licon RNA copies per sample analyzed in experiment B was determined by
quantitative PCR (qPCR), with an average of 16,500 and minimum of 2,600
replicon RNA copies.
The NS3 protease region of a control plasmid was processed in parallel. Based
on the variation observed on the control plasmid, the limit of detection was
deﬁned as a frequency of 0.4% for mutations in single samples (data not shown).
Percentages below 0.4% were considered if the same mutations were also
present in previous or subsequent samples.
Transient replicon assay. The transient replicon assay used to measure the
TMC380765 EC50s for wild-type and site-directed-mutants was described previ-
ously (24). In brief, Huh7 Lunet cells were transfected with in vitro-transcribed
replicon RNA from the wild type or mutants. Based on the luciferase lumines-
cence signal of compound-treated and control cells, EC50 (50% effective con-
centration) values were determined. EC50s of the mutants were compared to
those of the parental wild-type HCV replicon, and fold changes were calculated.
Replication capacity was determined in the absence of inhibitors as previously
described (28, 35) by measuring luciferase levels 48 h postelectroporation and
normalizing to the luciferase levels obtained 4 h postelectroporation.
RESULTS
Sanger population sequencing reveals TMC380765 concen-
tration-dependent resistance proﬁles. To assess the potential
differences in mutation proﬁles arising in the presence of dif-
ferent TMC380765 concentrations, Huh7-Luc replicon-con-
taining cells were cultured in the presence of G418 and either
100 nM or 1,000 nM or stepwise-increasing TMC380765 con-
centrations (ranging from 20 to 1,000 nM). Each selection
protocol was performed at least twice. Compound concentra-
tions used were well below the levels of toxicity for cell culture
(data not shown). At every passage, cell viability was scored
microscopically, and cells were harvested, total RNA was ex-
tracted, and the protease domain of the NS3 gene was se-
quenced using standard Sanger population sequencing. For
reasons of clarity, we will here limit our analysis to the six
amino acid positions (41, 43, 80, 155, 156, and 168) in NS3
known to affect binding and activity of macrocyclic NS3 pro-
tease inhibitors (20, 21, 24).
Different resistance proﬁles were observed in the low-con-
centration (100 nM) and high-concentration (1,000 nM) exper-
iments (Fig. 2). In the low-concentration selection experi-
ments, viability of the replicon-containing cells was not
affected. In the high-concentration selection experiments, lim-
ited initial cell death was followed by recovery of the cell
culture. During low-concentration selection, F43S/F mixtures
were very rapidly detected, and these remained present at each
time point analyzed until the end of the experiment, whereas in
the high-concentration selection experiment, mixtures of
A156A/V and D168A/D/V were detected after cell recovery. In
addition, at some time points during low-concentration selec-
tion, A156A/G and A156A/G/V mixtures were transiently ob-
served. No mutations at residue F43 were detected in the
high-concentration experiment, whereas no mutations at resi-
due D168 were present in the experiment with low concentra-
tions. In these experiments, changes at NS3 amino acid posi-
tion 41, 80, or 155 were not observed.
Population sequence analysis of samples from experiments
with stepwise-increasing TMC380765 concentrations sug-
gested three phases in the development of resistance (Fig. 2).
Initially F43F/S and/or A156A/G mixtures were observed,
whereas at the ends of the experiments, the mutations A156V
and A156A/V and D168D/V and D168A/V were present. This
is consistent with the mutation proﬁles observed in the low-
and high-concentration selection experiments, respectively. A
transition period can be assigned in the middle range of
TMC380765 concentrations used, in which, in addition to the
A156G and F43S mutations, the D168E/V or D168E/D/V and
A156A/G/V mutations were detected, reﬂecting a mixed pop-
ulation of resistant replicons. No mutation was detected at
position 41, 80, or 155. Mutations at other amino acid positions
in the NS3 region appeared to reﬂect background mutations
unrelated to TMC380765 pressure, since they were frequently
observed in untreated replicon-containing cell cultures as well
(24) or were detected only in combination with a mutation at
position 156 or 168. In all three experiments with increasing
TMC380765 concentrations, no effect on cell growth was ob-
served, indicating relatively stable HCV replication. This ob-
servation was conﬁrmed by qPCR analysis of samples from one
experiment (data not shown).
FIG. 2. Summary overview of mutations at NS3 protease positions
43, 156, and 168 detected by population sequencing during selection
experiments using 100 nM, 1,000 nM, and stepwise-increasing (0 to
1,000 nM) concentrations of TMC380765. It is important to note that
not every individual mutation was observed in each individual exper-
iment and that the majority were detected as mixtures of mutant and
wild-type amino acids. Each individual selection protocol was per-
formed at least twice.
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better assess the dynamics of changes in the replicon popula-
tion in experiments with increasing TMC380765 concentra-
tions, 454 deep sequencing was employed on samples of two
experiments (here referred to as experiments A and B). 454
deep sequencing widens the window of detection signiﬁcantly.
In contrast to population (bulk) Sanger sequencing, which
allows the detection of mutations present with a frequency of
at least 25%, 454 deep sequencing decreases the detection
limit to 0.5%. In addition, it allows quantiﬁcation of the
frequency of multiple replicon variants in parallel. The com-
plete sequence of the NS3/4A gene from replicons obtained in
experiment A was determined using the GS-FLX shotgun
technology, whereas for replicons obtained in experiment B,
only the protease domain of NS3 was sequenced with the
GS-FLX amplicon approach. As a control, Huh7-Luc replicon-
containing cells were passaged in parallel with experiment B
but in the absence of TMC380765 pressure, and replicon RNA
was sequenced by the GS-FLX amplicon approach.
Although the absolute mutation frequency levels varied be-
tween experiments A and B, the overall trends and patterns of
mutations emerging during increasing TMC380765 concentra-
tions were comparable between the two experiments.
In the pretreatment samples (Fig. 3A1 and B1 to A6 and
B6), mutations at NS3 amino acid positions 41, 80, and/or 156
were observed at frequencies between 0.3 and 2%. At position
41, the preexisting mutations Q41H and Q41R were ob-
served in both experiments. Interestingly, at position 80, the
mutation Q80R was present only in the pretreatment sample
from experiment A whereas the Q41K and A156G muta-
tions were present only in the pretreatment sample from
experiment B. In addition, at positions 80, 156, and 168, a
second codon was observed for the wild-type amino acid
variant (indicated with an apostrophe [’]); e.g., amino acid
D168 is encoded by GAC and the alternative codon GAT.
(Fig. 4).
In the control experiment, the preexisting mutations Q41H
and A156G were maintained at low frequencies (1%), as
were alternative wild types D168D’ and Q80Q’. In addition, at
two time points, F43S (0.5%) was observed. No amino acid
changes at position 80, 155, or 168 were detected.
During selection with TMC380765, the most pronounced
changes in amino acid frequencies occurred at the NS3 pro-
tease positions 156 and 168, where in total three (A156V,
A156T, and A156G) and ﬁve (D168A, D168E, D168V,
D168H, and D168Y) different mutations emerged. In addition,
changes were also noted at positions 41, 43, and 80; in each
case, one mutation (Q41R, F43S, and Q80R) dominated while
some other mutations were present at a low frequency (1%).
At position 155, only mutations R155Q and R155W emerged
in response to TMC380765 treatment, but they did not reach
frequencies above 1%. Mutations at positions 41, 43, and 80,
which emerged early during the selection experiments, domi-
nated the replicon population, with frequencies of up to 25%.
A further increase in TMC380765 concentrations resulted in a
decrease in the frequency of the latter mutations, with replicon
variants with mutations at NS3 protease positions 156 and 168
becoming dominant.
In more detail, the Q41R mutation (Fig. 3A1 and B1) in-
creased from 1% in the baseline sample up to maxima of 10
and 5% at 240 nM TMC380765 in experiments A and B,
respectively; subsequently, the frequency of Q41R decreased
and stabilized at 2 to 3%. F43S (Fig. 3A3 and B3) was detected
very early during both experiments at a frequency below 1%
and increased to 20 to 30% at 240 nM TMC380765 before
declining again below 1%. The frequency of the Q80R muta-
tion (Fig. 3A3 and B3) peaked at 20% in experiment A, where
it was present at 1% in the pretreatment sample. In experi-
ment B, Q80R was ﬁrst detected at 40 nM and only reached a
frequency of 5%. At higher drug concentrations, the Q80R
mutation stabilized at a frequency of 5% in both experiments.
In addition, in one or both experiments, the mutations Q41K,
Q41H, F43Y, F43L, F43C, Q80K, Q80H, and Q80L were
present as minorities with frequencies around 1%.
Interestingly, in experiment B, the frequency of the A156G
mutation increased signiﬁcantly, from pretreatment levels of
0.8% (Fig. 3C5) to 25% at 240 nM TMC380765, followed by
a decline to 8% at the end of the experiment, whereas this
mutation was not detected before treatment and was present
only transiently as a minority variant in experiment A. With
further-increasing TMC380765 concentrations, the A156V
mutation became the dominant mutation at position 156 (Fig.
3A5 and B5), reaching a frequency of 10 to 15% at the end of
the selection experiment (Fig. 3A5 and B5). The frequency of
the A156T mutation increased to 10% at a TMC380765
concentration of 320 nM, after which its frequency declined to
1t o5 % .
At position 168, the ﬁve amino acid changes detected can be
classiﬁed into two groups, deﬁned by the concentration range
of TMC380765 at which they emerged (Fig. 3A6 and B6). In
both experiments, the initial group of mutations was ﬁrst de-
tected at or below a TMC380765 concentrations of 80 nM, with
frequencies of 1%. They consisted of D168V, D168A, and
D168E. The mutations D168Y and D168H emerged in both
experiments at concentrations at or above 240 nM. Frequen-
cies of the mutations D168A and D168V increased rapidly, to
20 to 30%. D168E displayed a similar rapid increase in fre-
quency (up to 10 to 15%), but in contrast to D168A and
D168V (which remained present at these high frequency lev-
els), its prevalence decreased again toward the end of the
selection experiment (3 to 7%). In addition, in experiment A,
mutation D168Y also reached a high frequency (20%),
whereas in experiment B, it showed only a slight increase in
frequency, to 2% (similar to what was observed for D168H in
both experiments). Interestingly, the mutations D168V’,
D168A’, and D168E’, which are encoded by an alternative
codon, were observed at different time points. The codons for
these three mutations differ by one nucleotide from the alter-
native wild-type codon for D168D’, whereas there is a two-
nucleotide difference from the major wild-type codon. The
frequency of the alternative mutation D168V’ increased in
parallel with that of D168V, although delayed in time, reaching
its maximum frequency of 10% at the end of the selection
experiment. In contrast, the alternative mutations D168A’ and
D168E’ remained at average frequencies of around 1% dur-
ing the whole experiment.
Whereas our analysis focused on speciﬁc amino acid posi-
tions, other mutations in the NS3 protease gene that affect
susceptibility to a range of different HCV NS3/4A inhibitors
have been described (17). These mutations, such as V36A,
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low frequencies. None of these mutations appeared to contrib-
ute signiﬁcantly to the HCV replicon mutation proﬁle. In ad-
dition, compensatory mutations, such as Q86R, P89L, and
G162R (55), known to boost the replication capacity of some
resistance mutations, were detected. However, there was no
clear linkage with any of the resistance mutations since they
were already detected in the pretreatment samples. Moreover,
their frequencies did not change markedly with increasing
TMC380765 concentrations. It is important to note that
changes at other NS3 or NS4A positions were limited and that
no consistent pattern was observed, with the exception of
changes in the frequency of different codons encoding wild-
type amino acids, suggesting that these were linked with mu-
tations at the positions described.
Mutations confer various degrees of resistance in a tran-
sient replicon assay. To study the impact of the mutations
identiﬁed in the different selection experiments on the activity
of TMC380765, mutant replicons were generated by site-di-
rected mutagenesis and the sensitivity to TMC380765 was as-
sessed in a transient replicon assay (Fig. 5). The mutations
observed in the low-concentration selection experiment or at
the early or intermediate stages of the experiments with in-
creasing concentrations resulted in reduced susceptibility,
ranging from 2-fold for Q80R up to 50-fold for D168E. In
contrast, the mutations D168V and A156V, selected by high
concentrations of TMC380765, resulted in a greater than 500-
fold reduction in susceptibility, whereas D168A conferred a
90-fold change in drug sensitivity.
The replication capacities of the different mutant replicons
were determined as a measure of viral ﬁtness using standard
procedures (28, 35). The luciferase signal at 48 h posttransfec-
tion was normalized to the signal obtained at4ht ocorrect for
differences in transfection efﬁciencies, and the replication ca-
pacities of mutants were calculated relative to that of the wild
type. Overall, most mutants showed reduced replication capac-
ity levels compared to the wild type (Fig. 5).
Replicon sequences carrying more than one mutation. Se-
quence analysis of the selection experiments revealed amino
acid changes at multiple positions in many samples occurring
simultaneously. Neither the population sequencing nor the 454
deep sequencing protocol applied here allows the determina-
tion of mutation linkage, that is, that speciﬁc changes are on
the same replicon genome. In the case of 454 deep sequencing,
only mutations closer than 250 bp can be linked due to the
limited read length. To overcome this technical limitation,
single-genome sequencing using a clonal approach was per-
formed. Starting with the RNA samples, the full NS3 protease
domain was ampliﬁed by RT-PCR and bacterially cloned (24
or 48 clones were picked per sample for samples of experiment
A or B, respectively), followed by DNA sequencing of individ-
ual clones. Overall, the individual amino acid frequencies cor-
related well between clonal and 454 deep sequencing (data not
shown). However, clonal sequencing revealed that the seeming
persistence of the individual single low-level resistance muta-
tions F43S, A156G, Q41R, and Q80R at frequencies between
5 and 10% at the highest TMC380765 concentrations, as
shown by 454 deep sequencing, was due mainly to the occur-
FIG. 3. Codon frequencies at six key amino NS3 acid positions (41, 43, 80, 155, 156, and 168; indicated by 1 to 6, respectively) of selection
experiment with stepwise-increasing TMC380765 concentrations (A and B) or in the absence of NS3/4A inhibitor (C), as determined by 454
GS-FLX shotgun (A) or 454 GS-FLX amplicon (B and C) deep sequencing. Frequencies of individual amino acids were calculated as the number
of sequence reads per speciﬁc codon divided by the total number of reads at that codon position. Dotted lines connect points where no intermittent
data points were available. Alternative codon usage is indicated by an apostrophe (’). Based on 454 deep sequencing results of replicon control
plasmid (data not shown), the limit of detection was set at 0.4%; therefore, single-codon frequencies below 0.4% were excluded from this analysis.
However, percentages below 0.4% were considered signiﬁcant if mutants were present in previous or subsequent samples.
FIG. 4. Codon usage of amino acids detected by 454 deep sequenc-
ing during selection experiments at NS3 protease position D168. Two
wild-type codons, GAC and GAT, coding for aspartate (D), are shown
in the middle box. Boxes on the left and right show mutations detected
that are one nucleotide change away from wild-type codons GAC and
GAT (nucleotide changes resulting in amino acid changes are under-
lined).
FIG. 5. Change in TMC380765 susceptibility (EC50) and replica-
tion capacity (RC) values determined using a transient replicon assay
with replicons harboring single or double mutations in the NS3 pro-
tease domain. Fold change in EC50  EC50 mutant/EC50 clone ET
measured at 48 h. RC  (Luc48h_mut/Luc48h_ET)/(Luc4h_mut/
Luc4h_ET), where Luc48h_mut or -ET and Luc4h_mut and -ET are
luciferase levels of the mutant or the ET clone at 48 h and 4 h
postelectroporation, respectively. Inverted triangles, diamonds, and
upright triangles indicate amino acid changes detected primarily dur-
ing low, middle-range, and high TMC380765 concentration selection,
respectively. Double mutants are indicated by full circles.
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addition to these low-level resistant mutations. In contrast, the
mutations A156V and D168V, which reduced TMC380765 po-
tency signiﬁcantly by themselves, were observed mainly as sin-
gle mutant variants at the end of the selection experiment,
although some double/triple mutant variants were detected at
lower frequencies (Fig. 6B). These observations were con-
ﬁrmed by clonal analysis of samples from experiment A (24
clones/sample).
Clonal analyses further revealed that with increasing
TMC380765 concentrations, the overall wild-type population
(sequences carrying no mutation at amino acid positions 41,
43, 80, 155, 156, and/or 168) was totally replaced by mutant
variants (Fig. 7A to C). In the pretreatment sample, 44/47
clones (94%) had wild-type amino acids at the selected po-
sitions, whereas 3 clones carried either the F43Y, Q80H, or
A156G mutation. Interestingly, the F43Y and Q80H mutations
were not detected by 454 deep sequencing, whereas the A156G
mutation was observed with a frequency of 0.8% using 454
deep sequencing. At a TMC380765 concentration of 560 nM,
wild-type replicon sequences were reduced to 7/44 clones
(15%), while the number of clones with a single (26/44 clones
tested; 60%) or double (11/44 clones tested; 25%) muta-
tion increased (Fig. 6B). At the highest concentration ranges,
no wild-type sequences were detected. Single mutant variant
frequency increased to 75% (33/45 clones) of the population,
whereas the prevalence of variants carrying double mutations
remained constant at 25% (12/45 clones). Interestingly,
strains carrying three (R155W, A156V, and D168Y) or even
four (F43Y, Q80R, A156G, and D168V) mutations were ob-
served. Overall, a large variety of double mutant variations was
detected. The great majority (95%) of all the double mutant
genomes detected contained combinations of the low-level re-
sistance mutations Q41R, F43S, Q80R, and/or A156G with
either high-level resistance mutations (50%), intermediate-
level resistance mutations (such as D168E and/or A156T
[15%]), or combinations of two low-level resistance mutations
FIG. 6. Combined amino acid frequencies determined by clonal
sequencing for mutations Q41R, F43S, Q80R, and A156G (A) (mu-
tations with change in EC50s  15-fold) or A156V and D168V
(B) (mutations with change in EC50s  500-fold) in experiment B. For
every group, the frequency of genomes/clones harboring single or
multiple mutations is shown.
FIG. 7. Amino acid frequencies at a TMC380765 concentration of 20 nM (A), 560 nM (B), or 880 nM (C) detected by clonal sequencing. “wt”
indicates wild-type sequences carrying no mutations at any of the six key NS3 protease amino acid positions (41, 43, 80, 155, 156, and 168).
Sequences carrying single mutations are marked in gray. Sequences carrying multiple mutations are highlighted in color.
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only the highest compound concentrations, combinations of
two high-level resistance mutations (A156V and D168V) also
were present. Analysis of 4 selected double mutations, with
combinations of different types of mutations (i.e., combination
of low-level with low- or intermediate-level resistance and
combination of two high-level resistance mutations) in a tran-
sient replicon assay, showed either an increase in the fold
change of EC50 values or replication capacity or an increase in
both fold change and replication capacity for the double mu-
tants compared to the respective single mutants (Fig. 5).
DISCUSSION
In this study, the mutational patterns at six key positions of
NS3 (41, 43, 80, 155, 156, and 168) emerging in HCV replicon-
containing cells that were cultured in the presence of various
concentrations of the HCV NS3/4A protease inhibitor
TMC380765 were assessed. To this end, we employed popula-
tion, clonal, and 454 deep sequencing technologies.
Concentration-dependent mutational patterns were ob-
served: low concentrations of TMC380765 selected for muta-
tions conferring a low change in EC50s, as assessed in a tran-
sient replicon assay (such as the mutations F43S or A156G),
whereas selection with high concentrations of TMC380765 re-
sulted in the emergence of mutations conferring a high change
(such as D168A, D168V, and A156V). In experiments in which
the concentration of TMC380765 was increased stepwise, low-
level resistance mutations were initially detected by population
sequencing, whereas at a higher concentration of TMC380765,
these mutant replicons were replaced by replicons carrying
mutations conferring a high level of resistance.
A detailed analysis of the selection experiments by clonal
and 454 deep sequencing allowed better assessment of the
dynamic changes of the replicon population under increasing
selective pressure from TMC380765. This technology also al-
lowed the detection of low-frequency mutations not detectable
by population sequencing. Overall, many mutations in NS3
previously associated with exposure to NS3/4A protease inhib-
itors (reviewed in reference 17) were observed during the se-
lection experiments. However, as expected for a macrocyclic
NS3 protease inhibitor (7, 24) with a large S2 group and con-
sistent with the results from population sequencing, the most
pronounced amino acid changes in selection experiments with
TMC380765 were detected at NS3 positions 156 (3 different
mutations) and 168 (5 different mutations). As determined by
454 deep sequencing in the experiments with stepwise-increas-
ing TMC380765 concentrations, initial low concentrations se-
lected for a mixed pool of replicons carrying the low-level
resistance mutations Q41R, F43S, Q80R, and A156G at fre-
quencies between 10 and 25%, which were suppressed with
increasing TMC380765 concentrations and gradually replaced
by replicons carrying the high-level resistance mutations
A156V, D168A, and D168V. Interestingly, mutations causing
small changes in susceptibility were still detected at high
TMC380765 concentrations but, as clonal sequencing analysis
revealed, primarily in combination with other resistance mu-
tations, probably resulting in phenotypes conferring a higher
level of resistance to TMC380765. Phylogenetic analysis of the
clonal sequences did not allow assessment of whether these
double mutant variants were the result of the acquisition of
additional resistance mutations in addition to the initial or
preexisting mutation or whether variants carrying two or more
mutations were newly emerging (data not shown). Mutations
conferring high-level resistance (such as D168V and A156V)
were present predominantly as single unlinked mutations. No
or very few changes were observed beyond the six key positions
(41, 43, 80, 155, 156, and/or 168) of the NS3 protease or
NS3/4A gene during selection.
It has been reported that mutations need to be present at a
certain frequency to result in a measurable phenotypic effect
(32, 38). In total, 28 different amino acid changes were de-
tected at the six key positions, of which only ﬁve changes
reached a frequency of approximately 25%. At least half of
these 28 amino acid changes did not reach frequencies higher
than 10%, of which again half emerged and remained present
as a minority, with an average frequency of 1%. Clonal se-
quencing, however, revealed that with increasing concentra-
tions of TMC380765, the number of sequences carrying one or
more resistance mutations increased, reaching levels close to
100% at the end of the selection experiments. The contribution
of all these individual variants to the resistant phenotype of the
replicon population is not fully understood and remains a
possible subject for further studies.
The level of resistance (measured by the change in EC50s)
conferred by a mutation is a major determinant of viral survival
under drug pressure. In addition, replication capacity and,
more speciﬁcally, replication capacity in the presence of a drug
is regarded as a factor critical in predicting the emergence and
evolution of mutant viruses during drug treatment (14, 29).
As a third factor, the variants present before treatment in-
ﬂuence the emerging mutational patterns (1). The high muta-
tion rate of the HCV polymerase and the detection of multiple
mutant replicon variants early during the experiment suggest
the presence of many replicon variants at baseline. For exam-
ple, the A156G mutation, which was detected at baseline in
experiment B at 0.8%, reached a maximal frequency of 24% at
400 nM TMC380765, whereas in experiment A, A156G was
not detected at baseline and became only transiently detect-
able during selection, at an average frequency of 1%. Thus,
the higher preexisting frequency of A156G in experiment B
seems to confer an advantage in the competition for resources
and therefore an initial dominance, consistent with the mech-
anism suggested by the clonal interference model (33) and in a
recently described multivariant, viral dynamic model of geno-
type 1 HCV (1). In addition, the D168V mutation was not
detected in pretreatment samples and did not emerge imme-
diately at low compound concentrations, although it has the
most favorable replication capacity and resistance proﬁle in
vitro of all mutations detected in our experiments. This obser-
vation is puzzling and may be related to the absence or very
low frequency of this mutation at baseline. Additional studies
are needed to better understand the importance of preexisting
mutations for the selection and emergence of replicon variants
during compound treatment.
For HIV, it has been reported that codons specifying the
same amino acid can lead to different pathways of amino acid
substitution by single nucleotide changes, a phenomenon
called “quasisynonymy” (18). Similarly, for HCV, in vitro and
in vivo exposure to some HCV protease inhibitors favors an
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mutation is rarely observed in genotype 1b, probably due to the
fact that in genotype 1a only one nucleotide change is needed
for this mutation whereas in genotype 1b two nucleotide
changes are required (17, 24, 31). Here we have described, to
our knowledge for the ﬁrst time, the presence of two codons
encoding wild-type amino acids within one population of rep-
licons and the potential contribution of both codons to the
emergence of amino acid variants. Although not proven exper-
imentally, it can be assumed that, as shown in Fig. 4, at position
168 the codons for the resistant amino acids valine (V; GTC)
and alanine (A; GCC) have the major wild-type amino acid
aspartate (D; GAC) as an ancestor while the alternative resis-
tance mutations valine (V’; GTT) and alanine (A’; GCT) are
derived from the minority wild-type aspartate (D’; GAT). The
presence of such second wild-type amino acid codons within
one population may facilitate alternative pathways to resis-
tance, bringing an extra dimension to the mutational space
available for the virus to explore and allowing it to adapt even
more rapidly to changing environments (45). Analysis of a
large group of genotype 1a and 1b patient NS3 protease nu-
cleotide sequences extracted from the Los Alamos database
reveals that 93 and 7%, respectively, were carriers of the major
wild-type codon (D; GAC) and the alternative wild type (D’;
GAT) at position 168 (data not shown).
In summary, the in vitro resistance proﬁle of the macrocyclic
HCV NS3/4A inhibitor TMC380765 and the changes in qua-
sispecies composition during selection in vitro were assessed
using state-of-the-art sensitive sequencing technologies. De-
pending on the concentration of TMC380765 used during the
in vitro resistance selection experiments, distinct mutational
patterns were selected. This resulted in the emergence and
disappearance of multiple replicon variants in response to the
increasing selection pressure. In addition, clonal and 454 deep
sequencing analysis of the viral sequences in these experiments
enabled identiﬁcation of low-frequency mutations present at
baseline (preexisting mutants), which may contribute to the
mutational pattern that emerges. The presence of two alterna-
tive codons for wild-type amino acids at certain NS3 positions
within a single population of replicons is described and is
proposed to contribute to the emergence of the drug-resistant
geno- and phenotypes. Deep sequencing technologies, in con-
junction with clonal sequencing, are a powerful tool for gaining
a more profound insight into the dynamics of resistance acqui-
sition in the HCV quasispecies population during antiviral
drug pressure.
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